Dermata's first revenue is tiny, and its cash is nearly spent
The dermatology company booked $74,000 from an online skincare product in its first revenue quarter, while holding $5.0m and guiding to funding only into early 2027.
Dermata Therapeutics has begun generating revenue, but the amount is small against the cash it has left. The US company said third-quarter 2026 net sales were $74,000, the first revenue it has reported, following the 25 August online launch of its Tome Foundational Treatment skincare product.
At the end of the quarter Dermata held $5.0m in cash. It said that funding should last into the first quarter of 2027. On those figures, the company has only a short window before it must raise more money or find another source of funds.
The revenue comes from a cosmetic product sold online, not from a medicine approved through a drug pathway. That means the first commercial step sits outside the usual market-access routes of pharmaceutical launches. The company's results summary did not say how the $74,000 breaks down by period or channel.
Dermata has also started a clinical trial of Tome Clearing Treatment, a salicylic acid product for acne, and is aiming for a launch in the first half of 2027. The material available for this report did not include the trial's design or size, the product's regulatory classification, or the company's costs, so it is not possible to say how the planned launch fits with the funding timeline.
Why it matters
- First revenue is modest at $74,000, and the available results do not show how much of it is likely to recur.
- With $5.0m in cash and funding guided only into Q1 2027, the company's near-term financing needs are a key issue for any prospective partner or supplier.
- The acne product's targeted first-half 2027 launch falls close to the end of the stated funding horizon, though the regulatory pathway and trial details were not disclosed.
Company's press release (SEC filing): Dermata Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
